Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amplia Therapeutics's share price for the quarter that ended in Sep. 2023 was $0.0495. Amplia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 199.62 Mil. Therefore, Amplia Therapeutics's market cap for the quarter that ended in Sep. 2023 was $9.88 Mil.
Amplia Therapeutics's quarterly market cap
declined
from Sep. 2022 ($14.23 Mil) to Mar. 2023 ($12.97 Mil) and
declined
from Mar. 2023 ($12.97 Mil) to Sep. 2023 ($9.88 Mil).
Amplia Therapeutics's annual market cap
increased
from Mar. 2021 ($21.39 Mil) to Mar. 2022 ($21.40 Mil) but then
declined
from Mar. 2022 ($21.40 Mil) to Mar. 2023 ($12.97 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amplia Therapeutics's Enterprise Value for Today is $5.86 Mil.
Amplia Therapeutics Market Cap Historical Data
The historical data trend for Amplia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amplia Therapeutics's Market Cap
For the Biotechnology subindustry, Amplia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's Market Cap falls into.
Amplia Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amplia Therapeutics's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (OTCPK:INNMF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amplia Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Amplia Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Amplia Therapeutics (Amplia Therapeutics) Business Description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INNMF has been successfully added to your 